Corbus is a close-knit team of over 150 employees who are high-achievers, innovative, creative and, above all else, passionate about what we do. We hire for personality as well as for skill.
You must thrive in an entrepreneurial and autonomous environment where you will succeed based on your contribution and work ethic, not on your title or rank. At Corbus we take pride in our “family” atmosphere where each person’s contribution is vital to our success. As a Corbus employee, you are empowered to think creatively and be proactive in your approach. There is no place for politics or red tape here. Positive, team-oriented people work at Corbus and are rewarded with fun perks like weekly food deliveries to our kitchen, a monthly in-house massage therapist, company-paid classes with Title Boxing, and organized company activities and outings. Additionally, Corbus offers an attractive, comprehensive benefits package.
Corbus Pharmaceuticals Holdings, Inc. (NASDQ: CRBP) is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, Lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist specifically designed to eliminate blood-brain barrier penetration and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. CRB-4001 is scheduled to enter a Phase 1 study in 2019 followed a National Institutes of Health (NIH)-funded first-in-patient Phase 2 study.
Corbus Pharmaceuticals Holdings, Inc. is an equal opportunity employer
Senior Clinical Research Associate (Sr. CRA)
The Senior CRA is a seasoned professional with wide-ranging experience and a thorough understanding of GCP and ICH principles. The experienced Senior CRA identifies and resolves complex issues where an analysis of situations and data requires an in-depth evaluation of multiple factors. Exercising sound judgement in selecting methods and techniques and evaluating criteria for resolving issues, the Senior CRA will establish strong, positive relationships with both internal and external partners. The successful candidate contributes to the determination or development of methods and procedures at the project and company levels.
The Senior CRA may act as a CRA team lead and must be self-motivated, independent and able to work in a small team environment. The successful candidate will be a highly organized individual who can also multitask and adjust direction based on changing project/corporate priorities. Mentoring and helping train less experienced CRAs will be important. Acting as the primary point of contact for investigator sites being responsible for ensuring the clinical trial is conducted according to CFR, ICH and GCP guidelines is a must. The Senior CRA is efficient at executing monitoring and other clinical trial management activities while tracking the progress of assigned studies/projects and identifying and resolving challenges to achieve target objectives.
The CRA II/III is a self-motivated individual able to work in a small-team environment and to independently identify tasks/issues of critical importance. In this role, you will develop a thorough knowledge of GCP, ICH and CFR principles. The successful candidate will be a highly-organized individual who can multitask and adjust direction based on changing project/corporate priorities.
As the primary point of contact for investigator sites, the CRA II/III ensures the clinical trial is conducted according to appropriate guidelines and protocols. You will be responsible for the efficient execution of monitoring and other clinical trial management activities while tracking the progress of assigned studies and project. Pr